---
type: "Symbol"
title: "SL PHARM (002038.SZ) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/002038.SZ/topics.md"
symbol: "002038.SZ"
parent: "https://longbridge.com/en/quote/002038.SZ.md"
count: 3
datetime: "2026-03-14T18:53:08.361Z"
locales:
  - [en](https://longbridge.com/en/quote/002038.SZ/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002038.SZ/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002038.SZ/topics.md)
---

# SL PHARM (002038.SZ) — Community Discussions

### [Changfeng Pharmaceuticals, public offering received a record 6697.80 times oversubscription, 02652.HK—new share placement details](https://longbridge.com/en/topics/34936778.md)

- Author: [atzdxxm](https://longbridge.com/en/profiles/15083494.md)
- Datetime: 2025-10-08T09:05:55.000Z
- Comments: 0
- $CF PHARMTECH(02652.HK) opened with a 200% surge, reaching the peak directly at the opening, leaving those who bought at the opening in heavy losses. Nowadays, new stocks directly hit their peak at th

### [手握 10 个创新药，12 条三期管线！恒瑞医药，何时能走出至暗时刻？](https://longbridge.com/en/topics/1832502.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-01-17T09:11:22.000Z
- Comments: 2
- 正处于创新药转型关键时期的恒瑞医药，2021 年却接连陷入 “屋漏偏逢连夜雨” 的窘境：创下近十年来最差业绩、碘克沙醇注射液集采丢标、股价腰斩、市值暴跌……那么，作为已经手握 10 款创新药的 “医药一哥”，未来又能否突破 “至暗时刻”，并带领创新药板块重回巅峰呢？本文将从恒瑞的创新药管线及研发情况出发，剖析其转型背后的逻辑。 一、股价腰斩、市值暴跌...

**Comments:**

- **生财研习社 · 2022-06-07T14:21:20.000Z**: 个人还是看好恒瑞医药的，只是说现在整体的市场不景气，还需要耐心等待

### [突发机构抢筹，估值 70 亿！被显著低估的医药巨头，孵化出了一家超强的创新药资产！](https://longbridge.com/en/topics/1687559.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-01-03T03:29:20.000Z
- Comments: 0
- 2021 年 12 月 31 日，$SIHUAN PHARM(00460.HK) 全资子公司轩竹生物获得了超 6 亿元 B 轮投资，本轮融资由阳光人寿领投，倚锋资本、中冀投资、太金资本、国投泰康、海创母基金、中银资本、晋江轩弘、陕西金控、湾信资本、德诺资本、华医资本等知名投资机构跟投。凯乘资本担任本轮融资的独家财务顾问。本轮融资后，轩竹生物的估值已经达到 70 亿元，未来将持续加大创新药研发管线的

## References

- [SL PHARM (002038.SZ)](https://longbridge.com/en/quote/002038.SZ.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/002038.SZ/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002038.SZ/topics.md)